Evidence mapPaperPMID 41899560Full record

ReviewCancers2026

Mikel Portu, Mario Balsa, Maria Cotaina, Georgia Anguera, Xavier García Del Muro, Ferran Algaba, Pablo Maroto

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mikel PortuMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.ORCID 0009-0007-6953-1490
Mario BalsaMedical Oncology Department, Catalan Institute of Oncology (ICO), 08908 L'Hospitalet de Llobregat, Spain.ORCID 0009-0001-3203-8682
Maria CotainaMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Georgia AngueraMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.ORCID 0000-0002-6060-1110
Xavier García Del MuroMedical Oncology Department, Catalan Institute of Oncology (ICO), 08908 L'Hospitalet de Llobregat, Spain.
Ferran AlgabaPathology Department, Fundació Puigvert, 08025 Barcelona, Spain.
Pablo MarotoMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinomas (RCCs) driven by

Indexed as

gene fusionimmune checkpoint inhibitorMiT-RCCprecision oncologyTFE3TFEBtranslocation renal cell carcinomatyrosine kinase inhibitor

Identifiers

PMID41899560
PMCPMC13025244

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.